ADMA Biologics Stock Executives


USD 3.64  0.19  5.51%   

ADMA Biologics employes about 527 people. The company is managed by 20 executives with a total tenure of roughly 80 years, averaging almost 4.0 years of service per executive having 26.35 employees per reported executive. Analysis of ADMA Biologics management performance can provide insight into the company performance. Note, employee sentiment is becoming a valuable factor that investors use to determine the amount of risk that may be associated with ADMA Biologics future performance.
Please continue to Trending Equities.
  Adam Grossman  CEO
President CEO, Director
  Jerrold Grossman  Chairman
Vice Chairman of the Board
  Steven Elms  Chairman
Chairman of the Board

ADMA Biologics Return on Sales


ADMA Biologics Management Team Effectiveness

ADMA Biologics has return on total asset (ROA) of (0.1078) % which means that it has lost $0.1078 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (0.6923) %, meaning that it created substantial loss on money invested by shareholders. ADMA Biologics management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities. As of December 9, 2022, Return on Investment is expected to decline to -30.19. In addition to that, Return on Average Assets is expected to decline to -31.95. ADMA Biologics Total Assets are projected to increase significantly based on the last few years of reporting. The past year's Total Assets were at 276.25 Million. The current year Current Assets is expected to grow to about 225.2 M, whereas Revenue to Assets are forecasted to decline to 0.25.
The current year Weighted Average Shares is expected to grow to about 150.6 M. The current year Weighted Average Shares Diluted is expected to grow to about 150.6 M

ADMA Biologics Workforce Comparison

ADMA Biologics is number one stock in number of employees category among related companies. The total workforce of Health Care industry is presently estimated at about 92,544. ADMA Biologics maintains roughly 527 in number of employees contributing less than 1% to equities under Health Care industry.

ADMA Biologics Profit Margins

The company has Profit Margin (PM) of (0.54) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.36) %, which suggests for every $100 dollars of sales, it generated a net operating loss of 0.0.

ADMA Biologics Insider Trading

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific ADMA Biologics insiders, such as employees or executives, is commonly permitted as long as it does not rely on ADMA Biologics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, ADMA Biologics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

ADMA Biologics Benchmark Summation

The output start index for this execution was zero with a total number of output elements of sixty-one. ADMA Biologics Price Series Summation is a cross summation of ADMA Biologics price series and its benchmark/peer.

ADMA Biologics Notable Stakeholders

An ADMA Biologics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as ADMA Biologics often face trade-offs trying to please all of them. ADMA Biologics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting ADMA Biologics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Adam Grossman - President CEO, DirectorProfile
Jerrold Grossman - Vice Chairman of the BoardProfile
Steven Elms - Chairman of the BoardProfile
Brian Lenz - CFOProfile
Eric Richman - Independent DirectorProfile
Dov Goldstein - Independent DirectorProfile
Bernhard Ehmer - DirectorProfile
Bryant Fong - Independent DirectorProfile
Lawrence Guiheen - Independent DirectorProfile
Alan Erck - VP of Sales and National AccountsProfile
Michael Goldstein - Sr CounselProfile
Neal Fitzpatrick - VP SalesProfile
Kaitlin Kestenberg - Project ComplianceProfile
Cyndi Tolman - VP ServicesProfile
Dr DPS - CoFounder ChairmanProfile
Drew Pantello - VP DevelProfile
PharmD BCOP - Ex EngagementProfile
James Mond - Chief Scientific and Medical OfficerProfile
Michael Least - VP OperationsProfile

About ADMA Biologics Management Performance

The success or failure of an entity such as ADMA Biologics often depends on how effective the management is. ADMA Biologics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of ADMA Biologics management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the ADMA Biologics management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for 2022
Return on Investment(27.98) (30.19) 
Return on Average Assets(29.61) (31.95) 
Return on Average Equity(62.46) (67.39) 
Return on Invested Capital(0.22) (0.24) 
Return on Sales(0.72) (0.78) 
The data published in ADMA Biologics' official financial statements usually reflect ADMA Biologics' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of ADMA Biologics. For example, before you start analyzing numbers published by ADMA Biologics accountants, it's critical to develop an understanding of what ADMA Biologics' liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of ADMA Biologics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, ADMA Biologics' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in ADMA Biologics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of ADMA Biologics. Please utilize our Beneish M Score to check the likelihood of ADMA Biologics' management to manipulate its earnings.

ADMA Biologics Workforce Analysis

Traditionally, organizations such as ADMA Biologics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare ADMA Biologics within its industry.

ADMA Biologics Manpower Efficiency

Return on ADMA Biologics Manpower

Revenue Per Employee122.5 K
Revenue Per Executive4 M
Net Loss Per Employee146.7 K
Net Loss Per Executive3.6 M
Working Capital Per Employee32.4 K
Working Capital Per Executive853.7 K
Today, most investors in ADMA Biologics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various ADMA Biologics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's per employee growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of ADMA Biologics per employee as a starting point in their analysis.

Per Employee

ADMA Biologics Per Employee Growth Over Time

Net Income Per Employee


ADMA Biologics Net Income Per Employee is projected to increase significantly based on the last few years of reporting. The past year's Net Income Per Employee was at (135,954)

Revenue Per Employee


ADMA Biologics Revenue Per Employee is projected to increase significantly based on the last few years of reporting. The past year's Revenue Per Employee was at 153,591
Please continue to Trending Equities. You can also try Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Complementary Tools for analysis

When running ADMA Biologics price analysis, check to measure ADMA Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ADMA Biologics is operating at the current time. Most of ADMA Biologics' value examination focuses on studying past and present price action to predict the probability of ADMA Biologics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move ADMA Biologics' price. Additionally, you may evaluate how the addition of ADMA Biologics to your portfolios can decrease your overall portfolio volatility.
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Transaction History
View history of all your transactions and understand their impact on performance
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Is ADMA Biologics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ADMA Biologics. If investors know ADMA Biologics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ADMA Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
716.3 M
Quarterly Revenue Growth YOY
Return On Assets
Return On Equity
The market value of ADMA Biologics is measured differently than its book value, which is the value of ADMA Biologics that is recorded on the company's balance sheet. Investors also form their own opinion of ADMA Biologics' value that differs from its market value or its book value, called intrinsic value, which is ADMA Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ADMA Biologics' market value can be influenced by many factors that don't directly affect ADMA Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ADMA Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine ADMA Biologics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ADMA Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.